Physician profile
John D Northup
NPI 1023232527
$11,789.87
in general payments reported to CMS, 2019-2025
60 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,269 · 2020: $1,466 · 2021: $2,445 · 2022: $1,640 · 2023: $821 · 2024: $1,380 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,968.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,510.92 | 2019-2025 | Repatha, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,292.48 | 2019-2025 | Relistor, Trulance |
| Novo Nordisk INC | $1,076.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $813.23 | 2021-2025 | |
| Gilead Sciences, INC. | $490.75 | 2020-2025 | Livdelzi |
| Qol Medical, LLC | $481.22 | 2022-2025 | Sucraid, Sucraid |
| Pfizer INC. | $429.20 | 2019-2025 | |
| Esperion Therapeutics, INC. | $370.94 | 2020-2024 | Nexletol |
| Lilly USA, LLC | $314.30 | 2019-2025 | Zepbound, Mounjaro |
| Radius Health, INC. | $292.38 | 2019-2024 | Tymlos |
| Ardelyx, INC. | $285.43 | 2022-2025 | Ibsrela |
| Amarin Pharma, INC. | $268.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $262.94 | 2021-2024 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.28 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $213.31 | 2019-2025 | Eohilia, Entyvio |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Northup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.